Candida auris is an emerging pathogen, considered as critical in the list of the World Health Organization fungal organisms. The aim of the study is to determine the mortality and hospital stay for Candida auris (C. auris) compared to other Candida species in adult patients with candidemia. A retrospective cohort of adults with candidemia was consolidated in 7 centres in Colombia between 2016 and 2021. The primary outcome was 30-day mortality, and the secondary outcome was hospital stay among survivors. Adjustment of confounding variables was performed using inverse probability weights of exposure propensity score (candidemia by C. auris), survival regression models (Weibull distribution), and a counting model (negative binomial distribution).244 (47.6%) of 512 patients with candidemia died within the first 30 days. Crude mortality in C. auris was 38.1% vs. 51.1% in Candida non-auris (CNA). In the Weibull model, mortality in the C. auris group was lower (adjusted HR: aHR- 0.69, 95% CI: 0.53¿0.90). Antifungal treatment also decreased mortality, with aHR 0.36 (95% CI 0.27¿0.47), while the presence of septic shock on patient progression increased it, with aHR 1.73 (95% CI 1.41¿2.13). Among the patients who survived, no differences on hospital stay were observed between the C. auris and the CNA groups, with an incidence rate ratio of 0.92 (95% CI: 0.68¿1.22). Mortality in patients with C. auris bloodstream infection appears lower when adjusted for numerous confounding variables regarding treatment and the presence of septic shock in patient progression. We identified no significant effect of C. auris on hospital stay in surviving patients.